BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Drug Development Requires Flexibility in Clinical Trial Design: Interview With ICRC-Weyer Clinical CRO


8/20/2012 10:31:12 AM

PRLog (Press Release) - Aug 20, 2012 - In a recent interview, Prof Dr. Geerd Weyer of ICRC-Weyer GmbH, a Berlin-based clinical contract research organization, claims that every clinical trial is unique and must be designed and treated as such.

What would accelerate drug development and delivery/time to market?

In the last few years, many large pharmaceutical companies have been contracting out clinical development services to single, globally acting service providers. They tend to believe that the globalization of drug development gives them strength and allows them to avoid friction in processes that they would have if they had multiple interfaces and vendors. They believe that this will help them save time and effort, but I consider this to be a one-sided view. Using the services of a niche or specialist provider could help them accelerate clinical development.

Would this limit innovation in any way?

When it comes to innovation, a service provider that can be flexible should be preferred. Smaller organizations are able to bring in study-specific solutions, while larger organizations can bring in productivity and efficiency as they are able to streamline and standardize services. There is a dichotomy between efficiency and productivity on the one side, and innovation on the other. However, standardization does not always work. Processes must be adapted to each study. Clinical development is a process where innovation and flexibility are needed, at least as much as standardization.

What is unique about your approach and philosophy?

We are well aware of the dichotomy I mentioned before, but our philosophy has always been one of cooperation and partnership with clients and other service providers; bringing together our own strengths as a flexible specialist with the strengths of other providers. Our philosophy is also reflected in the way we integrate services across departments. Likewise, our data systems are optimized to seamlessly integrate data from various sources, internal or external.

What is key to clinical research and trial success?

The key is to have the right data in high quality when needed. This can be achieved by recognizing the value that a specialist provider in that respective area can bring, and by not totally relying on standard solutions. There is no single way for succeeding in clinical development. Every trial is unique and must be designed and treated as such.

The interview was held by the Marcus Evans Group, organizer of the Evolution Summit meeting for the life sciences industry. ICRC-Weyer GmbH is a sponsor company at this year’s event.

About Prof Dr. Geerd Weyer:

Prof Dr. rer. nat. Geerd Weyer has held several research chairs at Goethe University Frankfurt am Main, University of Bayreuth, University of Freiburg, and Humboldt University of Berlin. He is an acclaimed author and co-author of numerous scientific publications and guidelines such as ‘International Scales For Psychiatry’ and ‘Alzheimer’s Disease Assessment Scale (ADAS)’.

Prof Weyer is founder and CEO of ICRC-Weyer GmbH, an all-phase contract research organization (CRO) based in Berlin, Germany , where he supports and supervises all clinical research projects and activities.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->